Population Pharmacokinetic Analysis of Bedaquiline‐Clarithromycin for Dose Selection Against Pulmonary Nontuberculous Mycobacteria Based on a Phase 1, Randomized, Pharmacokinetic S... von Kurosawa, Ken, Rossenu, Stefaan, Biewenga, Jeike, Ouwerkerk‐Mahadevan, Sivi, Willems, Wouter, Ernault, Etienne, Kambili, Chrispin

Volltext

JNJ‐4178 (AL‐335, Odalasvir, and Simeprevir) for 6 or 8 Weeks in Hepatitis C Virus‐Infected Patients Without Cirrhosis: OMEGA‐1 von Zeuzem, Stefan, Bourgeois, Stefan, Greenbloom, Susan, Buti, Maria, Aghemo, Alessio, Lampertico, Pietro, Janczewska, Ewa, Lim, Seng Gee, Moreno, Christophe, Buggisch, Peter, Tam, Edward, Corbett, Chris, Willems, Wouter, Vijgen, Leen, Fevery, Bart, Ouwerkerk‐Mahadevan, Sivi, Ackaert, Oliver, Beumont, Maria, Kalmeijer, Ronald, Sinha, Rekha, Biermer, Michael

Volltext

Simeprevir With Peginterferon and Ribavirin Leads to High Rates of SVR in Patients With HCV Genotype 1 Who Relapsed After Previous Therapy: A Phase 3 Trial von Forns, Xavier, Lawitz, Eric, Zeuzem, Stefan, Gane, Ed, Bronowicki, Jean Pierre, Andreone, Pietro, Horban, Andrzej, Brown, Ashley, Peeters, Monika, Lenz, Oliver, Ouwerkerk–Mahadevan, Sivi, Scott, Jane, De La Rosa, Guy, Kalmeijer, Ronald, Sinha, Rekha, Beumont–Mauviel, Maria

Volltext

Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomised, double... von Jacobson, Ira M, Prof, Dore, Gregory J, Prof, Foster, Graham R, Prof, Fried, Michael W, Prof, Radu, Monica, MD, Rafalsky, Vladimir V, Prof, Moroz, Larysa, Prof, Craxi, Antonio, Prof, Peeters, Monika, MSc, Lenz, Oliver, PhD, Ouwerkerk-Mahadevan, Sivi, PhD, De La Rosa, Guy, MD, Kalmeijer, Ronald, MD, Scott, Jane, PhD, Sinha, Rekha, PhD, Beumont-Mauviel, Maria, PhD

Volltext

Simeprevir with pegylated interferon alfa 2a or 2b plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-2): a randomised, double-bl... von Manns, Michael, Prof, Marcellin, Patrick, Prof, Poordad, Fred, Prof, de Araujo, Evaldo Stanislau Affonso, PhD, Buti, Maria, Prof, Horsmans, Yves, Prof, Janczewska, Ewa, MD, Villamil, Federico, Prof, Scott, Jane, PhD, Peeters, Monika, MSc, Lenz, Oliver, PhD, Ouwerkerk-Mahadevan, Sivi, PhD, De La Rosa, Guy, MD, Kalmeijer, Ronald, MD, Sinha, Rekha, PhD, Beumont-Mauviel, Maria, PhD

Volltext

Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and trea... von Lawitz, Eric, Prof, Sulkowski, Mark S, Prof, Ghalib, Reem, MD, Rodriguez-Torres, Maribel, MD, Younossi, Zobair M, Prof, Corregidor, Ana, MD, DeJesus, Edwin, MD, Pearlman, Brian, Prof, Rabinovitz, Mordechai, Prof, Gitlin, Norman, MD, Lim, Joseph K, MD, Pockros, Paul J, MD, Scott, John D, MD, Fevery, Bart, MSc, Lambrecht, Tom, MSc, Ouwerkerk-Mahadevan, Sivi, PhD, Callewaert, Katleen, MSc, Symonds, William T, PharmD, Picchio, Gaston, PhD, Lindsay, Karen L, MD, Beumont, Maria, MD, Jacobson, Ira M, Prof

Volltext

Telaprevir combination therapy in HCV/HIV co‐infected patients (INSIGHT study): sustained virologic response at 12 weeks final analysis von Montes, Marisa, Nelson, Mark, Marie Girard, Pierre, Sasadeusz, Joe, Horban, Andrzej, Grinsztejn, Beatriz, Zakharova, Natalia, Rivero, Antonio, Lathouwers, Erkki, Janssen, Katrien, Ouwerkerk‐Mahadevan, Sivi, Witek, James

Volltext

Simeprevir versus telaprevir with peginterferon and ribavirin in previous null or partial responders with chronic hepatitis C virus genotype 1 infection (ATTAIN): a randomised, dou... von Reddy, K Rajender, Prof, Zeuzem, Stefan, Prof, Zoulim, Fabien, Prof, Weiland, Ola, Prof, Horban, Andrzej, Prof, Stanciu, Carol, Prof, Villamil, Federico Guillermo, MD, Andreone, Pietro, Prof, George, Jacob, Prof, Dammers, Elisabeth, MSc, Fu, Min, MS, Kurland, Darryl, MD, Lenz, Oliver, PhD, Ouwerkerk-Mahadevan, Sivi, PhD, Verbinnen, Thierry, PhD, Scott, Jane, PhD, Jessner, Wolfgang, MD

Volltext

Clinical impact of pharmacokinetic interactions between the HCV protease inhibitor simeprevir and frequently used concomitant medications von Marra, Fiona, Höner zu Siederdissen, Christoph, Khoo, Saye, Back, David, Schlag, Michael, Ouwerkerk‐Mahadevan, Sivi, Bicer, Ceyhun, Lonjon‐Domanec, Isabelle, Jessner, Wolfgang, Beumont‐Mauviel, Maria, Kalmeijer, Ronald, Cornberg, Markus

Volltext

Pharmacokinetics of bound and unbound telaprevir in cirrhotic patients with moderate and severe hepatic impairment von Ouwerkerk-Mahadevan, Sivi, Halabi, Atef, Cieslarová, Blanka, Aerts, Indra, Witek, James, Van Solingen-Ristea, Rodica, Luo, Donghan

Volltext

Simeprevir plus peginterferon/ribavirin for HCV genotype 1-infected treatment-naïve patients in China and South Korea von Wei, Lai, Han, Tao, Yang, Dongliang, Heo, Jeong, Shang, Jia, Cheng, Jun, Chen, Xinyue, Xie, Qing, Kim, Ju-Hyun, Kalmeijer, Ronald, Ouwerkerk-Mahadevan, Sivi, Hoeben, Eva, Lenz, Oliver, Verbinnen, Thierry, Sinha, Rekha, Li, MengChun, Scott, Jane, Peeters, Monika, Witek, James

Volltext

Efficacy, safety, and pharmacokinetics of simeprevir, daclatasvir, and ribavirin in patients with recurrent hepatitis C virus genotype 1b infection after orthotopic liver transplan... von Forns, Xavier, Berenguer, Marina, Herzer, Kerstin, Sterneck, Martina, Donato, Maria Francesca, Andreone, Pietro, Fagiuoli, Stefano, Cieciura, Tomasz, Durlik, Magdalena, Calleja, Jose Luis, Mariño, Zoe, Shukla, Umesh, Verbinnen, Thierry, Lenz, Oliver, Ouwerkerk‐Mahadevan, Sivi, Peeters, Monika, Janssen, Katrien, Kalmeijer, Ronald, Jessner, Wolfgang

Volltext

Efficacy of telaprevir-based therapy in stable liver transplant patients with chronic genotype 1 hepatitis C von Forns, Xavier, Samuel, Didier, Mutimer, David, Fagiuoli, Stefano, Navasa, Miquel, Agarwal, Kosh, Berenguer, Marina, Colombo, Massimo, Herzer, Kerstin, Nevens, Frederik, Daems, Bjorn, Janssen, Katrien, Ouwerkerk-Mahadevan, Sivi, Kimko, Holly, Lathouwers, Erkki, Witek, James, Solingen-Ristea, Rodica Van

Volltext

Drug–Drug Interactions with the NS3/4A Protease Inhibitor Simeprevir von Ouwerkerk-Mahadevan, Sivi, Snoeys, Jan, Peeters, Monika, Beumont-Mauviel, Maria, Simion, Alexandru

Volltext

Clinical Pharmacokinetics of Ponesimod, a Selective S1P1 Receptor Modulator, in the Treatment of Multiple Sclerosis von Kruger, Terra M., Valenzuela, Belén, Thompson, Charles D., Ouwerkerk-Mahadevan, Sivi, Ruixo, Juan Jose Perez

Volltext

Elucidating the Plasma and Liver Pharmacokinetics of Simeprevir in Special Populations Using Physiologically Based Pharmacokinetic Modelling von Snoeys, Jan, Beumont, Maria, Monshouwer, Mario, Ouwerkerk-Mahadevan, Sivi

Volltext

SAT-341 Discovery of a pan-genotypic hepatitis E virus replication inhibitor von Zhang, Xin, Klöhn, Mara, Ouwerkerk-Mahadevan, Sivi, Jagst, Michelle, Vereyken, Liesbeth, Verboven, Peter, Todt, Daniel, Jonckers, Tim H.M., Coelmont, Lotte, Fletcher, Helen, Samby, Kirandeep, Koul, Anil, Neyts, Johan, Steinmann, Eike, Kaptein, Suzanne J.F.

Volltext

Efficacy and safety of simeprevir with PegIFN/ribavirin in naïve or experienced patients infected with chronic HCV genotype 4 von Moreno, Christophe, Hezode, Christophe, Marcellin, Patrick, Bourgeois, Stefan, Francque, Sven, Samuel, Didier, Zoulim, Fabien, Grange, Jean-Didier, Shukla, Umesh, Lenz, Oliver, Ouwerkerk-Mahadevan, Sivi, Fevery, Bart, Peeters, Monika, Beumont, Maria, Jessner, Wolfgang

Volltext

Effect of Ponesimod Exposure on Total Lymphocyte Dynamics in Patients with Multiple Sclerosis von Valenzuela, Belén, Pérez-Ruixo, Juan-José, Leirens, Quentin, Ouwerkerk-Mahadevan, Sivi, Poggesi, Italo

Volltext

Population Pharmacokinetic Modeling of JNJ-53718678, a Novel Fusion Inhibitor for the Treatment of Respiratory Syncytial Virus: Results from a Phase I, Double-Blind, Randomized, Pl... von Huntjens, Dymphy R. H., Ouwerkerk-Mahadevan, Sivi, Brochot, Anne, Rusch, Sarah, Stevens, Marita, Verloes, Rene

Volltext